Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 2
2005 8
2006 9
2007 6
2008 3
2009 4
2010 7
2011 4
2012 1
2013 2
2014 2
2015 7
2016 2
2017 1
2020 1
2021 7
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
Langley JM, Gantt S, Halperin SA, Ward B, McNeil S, Ye L, Cai Y, Smith B, Anderson DE, Mitoma FD. Langley JM, et al. Among authors: mitoma fd. Vaccine. 2024 Jan 25;42(3):713-722. doi: 10.1016/j.vaccine.2023.12.019. Epub 2023 Dec 22. Vaccine. 2024. PMID: 38142214 Free article. Clinical Trial.
PreHevbrio: the first approved 3-antigen hepatitis B vaccine.
Vesikari T, Langley JM, Popovic V, Diaz-Mitoma F. Vesikari T, et al. Among authors: diaz mitoma f. Expert Rev Vaccines. 2023 Jan-Dec;22(1):1041-1054. doi: 10.1080/14760584.2023.2274482. Epub 2023 Nov 6. Expert Rev Vaccines. 2023. PMID: 37877189 Free article. Review.
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
Vesikari T, Finn A, van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, Toma A, Vallieres G, Aronson R, Reich D, Arora S, Ruane PJ, Cone CL, Manns M, Cosgrove C, Faust SN, Ramasamy MN, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson D, Popovic V, Diaz-Mitoma F; CONSTANT Study Group. Vesikari T, et al. Among authors: diaz mitoma f. JAMA Netw Open. 2021 Oct 1;4(10):e2128652. doi: 10.1001/jamanetworkopen.2021.28652. JAMA Netw Open. 2021. PMID: 34636914 Free PMC article. Clinical Trial.
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
Fluckiger AC, Ontsouka B, Bozic J, Diress A, Ahmed T, Berthoud T, Tran A, Duque D, Liao M, McCluskie M, Diaz-Mitoma F, Anderson DE, Soare C. Fluckiger AC, et al. Among authors: diaz mitoma f. Vaccine. 2021 Aug 16;39(35):4988-5001. doi: 10.1016/j.vaccine.2021.07.034. Epub 2021 Jul 16. Vaccine. 2021. PMID: 34304928 Free PMC article.
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, Smith B, Gantt S, McElhaney JE, Dionne M, van Damme P, Leroux-Roels I, Leroux-Roels G, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson DE, Popovic V, Diaz-Mitoma F; PROTECT Study Group. Vesikari T, et al. Among authors: diaz mitoma f. Lancet Infect Dis. 2021 Sep;21(9):1271-1281. doi: 10.1016/S1473-3099(20)30780-5. Epub 2021 May 11. Lancet Infect Dis. 2021. PMID: 33989539 Clinical Trial.
68 results